

Table S1. Effects of AAPs on FIB, APTT, PT and TT in vitro

Sample	Concentration ($\mu\text{g/mL}$)	Clotting time (s)		
		APTT	PT	TT
<i>Saline</i>	-	28.0 ± 0.2	11.3 ± 0.1	17.7 ± 0.1
<i>Heparin</i>	2.5 IU/mL	$30.3 \pm 0.1^{**}$	$13.6 \pm 0.5^{**}$	$21.4 \pm 0.1^{**}$
	25 IU/mL	> 200	> 200	> 200
<i>AAP</i>	12.5	$28.9 \pm 0.1^{**}$	11.8 ± 0.1	$18.0 \pm 0.1^*$
	25	$31.3 \pm 0.3^{**}$	11.7 ± 0.1	$22.3 \pm 0.3^{**}$
	50	$31.9 \pm 0.2^{**}$	11.0 ± 0.2	$25.3 \pm 0.3^{**}$
<i>AAP-a</i>	12.5	28.3 ± 0.1	11.4 ± 0.2	16.5 ± 0.2
	25	28.4 ± 0.1	11.6 ± 0.1	16.3 ± 0.1
	50	28.4 ± 0.3	11.5 ± 0.2	16.6 ± 0.1
<i>AAP-b</i>	12.5	$36.0 \pm 0.1^{**}$	11.4 ± 0.2	$33.7 \pm 0.2^{**}$
	25	$48.4 \pm 0.3^{**}$	$12.6 \pm 0.2^{**}$	$42.4 \pm 0.2^{**}$
	50	$64.5 \pm 0.4^{**}$	$13.7 \pm 0.3^{**}$	$62.7 \pm 0.3^{**}$
<i>AAP-c</i>	12.5	26.2 ± 0.1	$16.2 \pm 0.2^{**}$	$20.3 \pm 0.1^{**}$
	25	27.5 ± 0.1	$26.6 \pm 0.2^{**}$	$21.8 \pm 0.2^{**}$
	50	$47.3 \pm 1.0^{**}$	$63.6 \pm 0.3^{**}$	$28.3 \pm 0.3^{**}$

* $P < 0.05$ represents significant difference and ** $P < 0.01$ represents extreme significant difference.




Figure S1. Mass spectra scanning of glycoside linkages of Manp-(1→ **(a)**, →3)-Manp-(1→ **(b)**, →4)-GlcP-(1→ **(c)** and →2,3)-Manp-(1→ **(d)**).

Abbreviations

Auricularia auricula polysaccharide, AAP; adenosine diphosphate, ADP; activated partial thromboplastin time, APTT; antithrombin III, AT-III; enzyme-linked immunosorbent assay, Elisa; endothelial nitric oxide synthases, eNOs; endothelin-1, ET-1; hematoxylin and eosin, H&E; high molecular weight kininogen, HMWK; inhibition rate of thrombus relative length, IR; protein C, PC; prostacyclin, PGI2; plasminogen, PLG; prothrombin time, PT; relative average tail length, RATL; tissue factor pathway inhibitor, TFPI; thrombin time, TT; thromboxane A2, TXA2; thromboxane B2, TXB2.